Pharmacologicalapproaches of binge drinking

Current Pharmaceutical Design

Volumn 17, Issue 14, 2011, Pages 1333-1342

  Rolland, Benjamin ^a,c   Karila, Laurent ^b   Guardia, Dewi ^a,c   Cottencin, Olivier ^a,c  

^a UNIV LILLE   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c NONE   (France)

Author keywords

Addiction; Adolescence; Alcohol; Alcohol withdrawal syndrome; Binge drinking; Craving; Impulsivity; Pharmacotherapy

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 4 HYDROXYBUTYRIC ACID; ACAMPROSATE; ALCOHOL; ARIPIPRAZOLE; BACLOFEN; BENZODIAZEPINE; CLOZAPINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DIAZEPAM; DISULFIRAM; FENOFIBRATE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALMEFENE; NALTREXONE; ONDANSETRON; PLACEBO; QUETIAPINE; TOPIRAMATE;

ADOLESCENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY; ARTICLE; BINGE DRINKING; CONFUSION; DRUG EFFECT; DRUG MECHANISM; DYSPHORIA; HALLUCINOSIS; HUMAN; IMPULSIVENESS; IRRITABILITY; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROBIOLOGY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REWARD; SEIZURE; SWEATING; ADDICTION; ADOLESCENT; ADULT; ALCOHOL INTOXICATION; ANIMAL; CHILD BEHAVIOR; DRINKING BEHAVIOR; HARM REDUCTION; PSYCHOLOGICAL ASPECT; TIME;

ADOLESCENT; ADOLESCENT BEHAVIOR; ALCOHOL DRINKING; ALCOHOL-RELATED DISORDERS; ALCOHOLIC INTOXICATION; ALCOHOLISM; ANIMALS; BEHAVIOR, ADDICTIVE; HARM REDUCTION; HUMANS; IMPULSIVE BEHAVIOR; TIME FACTORS; YOUNG ADULT;

EID: 79959975649     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796150792     Document Type: Article

References (125)

1. McArdle P. Alcohol abuse in adolescents. Arch Dis Child 2008; 93(6): 524-7.
2. Casey BJ, Jones RM, Hare TA. The adolescent brain. Ann N Y Acad Sci 2008; 1124: 111-26.
3. Tomsovic M. "Binge" and continuous drinkers: Characteristics and treatment follow-up. Q J Stud Alcohol. 1974; 35: 558-64.
4. Courtney, K.E.; Polich, J. Binge Drinking in Young Adults: Data, Definitions, and Determinants. Psychol Bull. 2009; 135(1): 142-56.
5. Wechsler H, Nelson TF. Binge drinking and the American college student: what's five drinks? Psychol Addict Behav 2001; 15(4):287-91.
6. Wechsler H, Davenport A, Dowdall G, Moeykens B, Castillo S. Health and behavioral consequences of binge drinking in college: A national survey of students at 140 campuses. JAMA 1994; 272:1672-7.
7. National Institute on Alcohol Abuse and Alcoholism. NIAAA Council Approves Definition of Binge Drinking, NIAAA Newsletter, No. 3. National Institute on Alcohol Abuse and Alcoholism;Bethesda, MD: 2004.
8. Cranford JA, Eisenberg D, Serras AM. Substance use behaviors, mental health problems, and use of mental health services in a probability sample of college students. Addict Behav. 2009; 34(2):134-45.
9. Littleton J. Receptor regulation as a unitary mechanism for drug tolerance and physical dependence--not quite as simple as it seemed! Addiction 2001; 96(1): 87-101.
10. Turner RC, Lichstein PR, Peden JG Jr, Busher JT, Waivers LE. Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment. J Gen Intern Med 1989; 4(5):432-44.
11. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol 2005; 5(1): 9-19.
12. Goodman A. Neurobiology of addiction. An integrative review. Biochem Pharmacol 2008; 75(1): 266-322.
13. Koob GF, Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 2008; 363(1507): 3113-23.
14. Fortuna JL, Smelson DA. The phenomenon of drug craving. J Psychoactive Drugs. 2008; 40(3): 255-61.
15. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35(1): 217-38.
16. de Bruijn C, van den Brink W, de Graaf R, Vollebergh WA. The craving withdrawal model for alcoholism: towards the DSM-V. Improving the discriminant validity of alcohol use disorder diagnosis. Alcohol Alcohol 2005; 40(4): 314-22.
17. Field, M.; Schoenmakers, T.; Wiers, R.W. Cognitive processes in alcohol binges: a review and research agenda. Curr Drug Abuse Rev 2008; 1(3): 263-79.
18. Crabbe JC, Harris RA, Koob GF. Preclinical studies of alcohol binge drinking. Ann N Y Acad Sci 2011; 1216(1): 24-40.
19. Crews FT, Boettiger CA. Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav 2009; 93(3): 237-47.
20. Blazer DG, Wu LT. The epidemiology of at-risk and binge drinking among middle-aged and elderly community adults: National Survey on Drug Use and Health. Am J Psychiatry 2009; 166(10):1162-9.
21. Martin CA, Kelly TH, Rayens MK, Brogli BR, Brenzel A, Smith WJ, Omar HA. Sensation seeking, puberty, and nicotine, alcohol, and marijuana use in adolescence. J Am Acad Child Adolesc Psychiatry. 2002; 41(12): 1495-502.
22. Crawford LA, Novak KB. Alcohol abuse as a rite of passage: the effect of beliefs about alcohol and the college experience on undergraduates' drinking behaviors. J Drug Educ 2006; 36(3): 193-212.
23. Westen D, Betan E, Defife JA. Identity disturbance in adolescence: Associations with borderline personality disorder. Dev Psychopathol 2011; 23(1): 305-13.
24. León JC, Carmona J, García P. Health-risk behaviors in adolescents as indicators of unconventional lifestyles. J Adolesc 2010; 33(5):663-71.
25. Neumark-Sztainer D. The social environments of adolescents: associations between socioenvironmental factors and health behaviors during adolescence. Adolesc Med 1999; 10(1): 41-55.
26. Shiner RL. The development of personality disorders: perspectives from normal personality development in childhood and adolescence. Dev Psychopathol 2009; 21(3): 715-34.
27. Steinberg L. Cognitive and affective development in adolescence. Trends Cogn Sci 2005; 9(2): 69-74.
28. Crews F, He J, Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol Biochem Behav 2007; 86(2): 189-99.
29. Romer D. Adolescent risk taking, impulsivety, and brain development: implications for prevention. Dev Psychobiol 2010; 52(3):263-76.
30. Adinoff B, Rilling LM, Williams MJ, et al. Impulsivity, neural deficits, and the addictions: the oops factor in relapse. J Addict Dis 2007; 26 Suppl 1: 25-39.
31. Salavert J, Gasol M, Vieta E, Cervantes A, Trampal C, Gispert JD. Fronto-limbic dysfunction in borderline personality disorder: A 18F-FDG positron emission tomography study. J Affect Disord 2011 (epub).
32. Goudriaan AE, Grekin ER, Sher KJ. Decision making and binge drinking: a longitudinal study. Alcohol Clin Exp Res 2007; 31(6):928-38.
33. Hingson RW, Edwards EM, Heeren T, Rosenbloom D. Age of drinking onset and injuries, motor vehicle crashes, and physical fights after drinking and when not drinking. Alcohol Clin Exp Res 2009; 33(5): 783-90.
34. Coghlan M, Macdonald S. The role of substance use and psychosocial characteristics in explaining unintentional injuries. Accid Anal Prev 2010; 42(2): 476-9.
35. Viner RM, Taylor B. Adult outcomes of binge drinking in adolescence: findings from a UK national birth cohort. J Epidemiol Community Health. 2007; 61(10): 902-7.
36. Bonomo YA, Bowes G, Coffey C, Carlin JB, Patton GC. Teenage drinking and the onset of alcohol dependence: a cohort study over seven years. Addiction 2004; 99(12): 1520-8.
37. Martinez JA, Steinley D, Sher KJ. Deliberate induction of alcohol tolerance: empirical introduction to a novel health risk. Addiction 2010; 105(10): 1767-70.
38. Maldonado-Devincci AM, Badanich KA, Kirstein CL. Alcohol during adolescence selectively alters immediate and long-term behavior and neurochemistry. Alcohol 2010; 44(1): 57-66.
39. Hingson RW, Heeren T, Winter MR. Age at drinking onset and alcohol dependence: age at onset, duration, and severity. Arch Pediatr Adolesc Med 2006; 160(7): 739-46.
40. Hill KG, White HR, Chung IJ, Hawkins JD, Catalano RF. Early adult outcomes of adolescent binge drinking: person- and variablecentered analyses of binge drinking trajectories. Alcohol Clin Exp Res 2000; 24(6): 892-901.
41. Abernathy K, Chandler LJ, Woodward JJ. Alcohol and the prefrontal cortex. Int Rev Neurobiol 2010; 91: 289-320.
42. Clark DB, Thatcher DL, Tapert SF. Alcohol, psychological dysregulation, and adolescent brain development. Alcohol Clin Exp Res 2008; 32(3): 375-85.
43. Crews FT, Mdzinarishvili A, Kim D, He J, Nixon K. Neurogenesis in adolescent brain is potently inhibited by ethanol. Neuroscience 2006; 137(2): 437-45.
44. Waszkiewicz N, Szajda SD, Zalewska A, Konarzewska B, Szulc A, Kepka A, Zwierz K. Binge drinking-induced liver injury. Hepatology 2009; 50(5): 1676.
45. Mathurin P, Deltenre P. Effect of binge drinking on the liver: an alarming public health issue? Gut 2009; 58(5): 613-7.
46. Crews FT, Nixon K. Mechanisms of neurodegeneration and regeneration in alcoholism. Alcohol Alcohol 2009; 44(2): 115-27.
47. Zuccoli G, Siddiqui N, Cravo I, Bailey A, Gallucci M, Harper CG. Neuroimaging findings in alcohol-related encephalopathies. AJR Am J Roentgenol 2010; 195(6): 1378-84.
48. Jung ME, Metzger DB. Alcohol withdrawal and brain injuries: beyond classical mechanisms. Molecules 2010; 15(7): 4984-5011.
49. Ha HL, Shin HJ, Feitelson MA, Yu DY. Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol 2010; 16(48): 6035-43.
50. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcoholinduced liver injury. Arch Toxicol 2009; 83(6): 519-48.
51. Yuan L, Zhou LJ, Li WM. Oxidative stress-induced apoptosis is mediated by calpains in alcoholic cardiomyopathy. Int J Cardiol 2010. (epub)
52. Vengeliene V, Bilbao A, Molander A, Spanagel R. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008; 154(2): 299-315.
53. Ron D, Wang J. The NMDA Receptor and Alcohol Addiction. In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton (FL): CRC Press; 2009. Chapter 4. Frontiers in Neuroscience.
54. Nevo I, Hamon M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 1995; 26(4): 305-36.
55. Olsen RW, Hanchar HJ, Meera P, Wallner M. GABAA receptor subtypes: the one glass of wine receptors. Alcohol 2007; 41(3): 201-9.
56. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010; (3):CD005063.
57. Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119(3): 276.e13-8.
58. Franken IH, Booij J, van den Brink W. The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol 2005; 526(1-3): 199-206.
59. Caputo F, Bernardi M. Medications acting on the GABA system in the treatment of alcoholic patients. Curr Pharm Des 2010; 16(19):2118-25.
60. Krystal JH, Staley J, Mason G, et al. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry 2006; 63(9): 957-68.
61. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75(1): 34-56.
62. Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99(7): 811-28.
63. Rösner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008; 22(1): 11-23.
64. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008; 2(7): 1105-10.
65. Umhau JC, Momenan R, Schwandt ML, et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 2010; 67(10): 1069-77.
66. Cowen MS, Adams C, Kraehenbuehl T, Vengeliene V, Lawrence AJ. The acute anti-craving effect of acamprosate in alcoholpreferring rats is associated with modulation of the mesolimbic dopamine system. Addict Biol 2005; 10(3): 233-42.
67. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008; 75(1): 218-65.
68. Kampman KM, Dackis C, Pettinati HM, Lynch KG, Sparkman T, O'Brien CP. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict Behav 2011; 36(3): 217-21.
69. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006; 26(3): 290-302.
70. Gaval-Cruz M, Weinshenker D. mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv 2009; 9(4): 175-87.
71. Schroeder JP, Cooper DA, Schank JR, et al. Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase. Neuropsychopharmacology 2010; 35(12):2440-9.
72. Soyka M, Rösner S. Nalmefene for treatment of alcohol dependence. Expert Opin Investig Drugs 2010; 19(11): 1451-9.
73. Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008; 33(3): 643-52.
74. Wechsler H, Nelson TF. Binge drinking and the American college student: what's five drinks? Psychol Addict Behav 2001; 15(4): 287-91.
75. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 2010; 210(2): 121-35.
76. Kenna GA. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des 2010; 16(19): 2126-35.
77. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000; 284(8): 963-71.
78. Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 2003; 27: 1150-5.
79. Johnson BA. Medication treatment of different types of alcoholism. Am J Psychiatry 2010; 167(6): 630-9.
80. Dawes MA, Johnson BA, Ma JZ, Ait-Daoud N, Thomas SE, Cornelius JR. Reductions in and relations between craving and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 2005; 30(9): 1630-7.
81. Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 2009; 56 Suppl 1: 18-31.
82. Swift R. Medications acting on the dopaminergic system in the treatment of alcoholic patients. Curr Pharm Des 2010; 16(19):2136-40.
83. Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008; 23(5): 417-24.
84. Vergne DE, Anton RF. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord Drug Targets 2010; 9(1): 50-4.
85. Beduin AS, de Haan L. Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol Bull 2010; 43(3): 45-81.
86. Saitz R. Baclofen for alcohol withdrawal: not comparable to the gold standard (benzodiazepines). Am J Med 2007; 120(6): e9;author reply e11.
87. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des 2010;16(19): 2113-7.
88. Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary doubleblind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009; 103(1-2): 30-6.
89. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, Foltin RW. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2010; 211(2): 233-44.
90. Colombo G, Addolorato G, Agabio R, et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res 2004; 6(5): 403-14.
91. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34(11): 1849-57.
92. Tanchuck MA, Yoneyama N, Ford MM, Fretwell AM, Finn DA. Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking. Alcohol 2011; 45(1): 33-44.
93. Nasrallah FA, Maher AD, Hanrahan JR, Balcar VJ, Rae CD. β-Hydroxybutyrate and the GABAergic footprint: a metabolomic approach to unpicking the actions of GHB. J Neurochem 2010;115(1): 58-67.
94. Ameisen O. Gamma-hydroxybutyrate (GHB)-deficiency in alcohol- dependence? Alcohol Alcohol 2007; 42(5): 506.
95. Nava F, Premi S, Manzato E, Campagnola W, Lucchini A, Gessa GL. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam. Am J Drug Alcohol Abuse 2007; 33(3): 379-92.
96. Koek W, Carter LP, Lamb RJ, Chen W, Wu H, Coop A, France CP. Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam. J Pharmacol Exp Ther 2005; 314(1): 170-9.
97. Sumnall HR, Woolfall K, Edwards S, Cole JC, Beynon CM. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend 2008; 92(1-3): 286-90.
98. Rawls SM, Thomas T, Adeola M, Patil T, Raymondi N, Poles A, Loo M, Raffa RB. Topiramate antagonizes NMDA- and AMPAinduced seizure-like activity in planarians. Pharmacol Biochem Behav 2009; 93(4): 363-7.
99. Simeone TA, Wilcox KS, White HS. Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors. Neuropharmacology 2006; 50(7): 845-57.
100. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 Suppl 6: S4-11.
101. Krupitsky EM, Rudenko AA, Burakov AM, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007; 31(4): 604-11.
102. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010; 71(5): 634-48.
103. Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28(1): 6-10.
104. Arbaizar B, Gómez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry 2008; 30(5): 471-5.
105. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361(9370): 1677-85.
106. Breslin FJ, Johnson BA, Lynch WJ. Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology (Berl) 2010; 207(4): 529-34.
107. Baltieri DA, Darò FR, Ribeiro PL, de Andrade AG. Comparing topiramate with natrexone in the treatment of alcohol dependence. Addiction 2008; 103(12): 2035-44.
108. Rubio G, Martínez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol 2009; 29(6): 584-9.
109. Book SW, Myrick H. Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs 2005; 14(4): 371-6.
110. Myrick H, Anton R, Voronin K, Wang W, Henderson S. A doubleblind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res 2007; 31(2):221-7.
111. Armario A. Activation of the hypothalamic-pituitary-adrenal axis by addictive drugs: different pathways, common outcome. Trends Pharmacol Sci 2010; 31(7): 318-25.
112. Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropinreleasing factor in drug addiction. Pharmacol Rev 2001; 53(2):209-43.
113. Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; 103(12): 2035-44.
114. Roberto M, Cruz MT, Gilpin NW, et al. Corticotropin releasing factor-induced amygdala gamma-aminobutyric Acid release plays a key role in alcohol dependence. Biol Psychiatry 2010; 67(9): 831-9.
115. Marinelli PW, Funk D, Juzytsch W, et al. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 2007; 195(3): 345-55.
116. Ji D, Gilpin NW, Richardson HN, Rivier CL, Koob GF. Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 2008; 19(1): 1-12.
117. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005; 19(6): 517-37.
118. Cippitelli A, Damadzic R, Frankola K, et al. Alcohol-induced neurodegeneration, suppression of transforming growth factor-beta, and cognitive impairment in rats: prevention by group II metabotropic glutamate receptor activation. Biol Psychiatry 2010; 67(9): 823-30.
119. Bugge A, Mandrup S. Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation PPAR Res 2010; 2010. pii: 169506. epub 2010.
120. Deplanque D, Gelé P, Pétrault O, et al. Peroxisome proliferatoractivated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003; 23(15): 6264-71.
121. Marche K, Danel T, Bordet R. Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARalpha agonist fenofibrate in a rat model. Psychopharmacology (Berl) 2010. Epub.
122. Mello T, Polvani S, Galli A. Peroxisome proliferator-activated receptor and retinoic x receptor in alcoholic liver disease. PPAR Res 2009; 2009: 748174.
123. Gyamfi MA, Wan YJ. Pathogenesis of alcoholic liver disease: the role of nuclear receptors. Exp Biol Med (Maywood). 2010; 235(5):547-60.
124. Stopponi S, Somaini L, Cippitelli A, et al. Activation of Nuclear PPARγ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking. Biol Psychiatry 2011. (epub)
125. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics:from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24(5): 737-42.